JP2021531005A5 - - Google Patents
Info
- Publication number
- JP2021531005A5 JP2021531005A5 JP2021502831A JP2021502831A JP2021531005A5 JP 2021531005 A5 JP2021531005 A5 JP 2021531005A5 JP 2021502831 A JP2021502831 A JP 2021502831A JP 2021502831 A JP2021502831 A JP 2021502831A JP 2021531005 A5 JP2021531005 A5 JP 2021531005A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- amino acid
- binding
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023117208A JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700596P | 2018-07-19 | 2018-07-19 | |
| US62/700,596 | 2018-07-19 | ||
| US201862750968P | 2018-10-26 | 2018-10-26 | |
| US62/750,968 | 2018-10-26 | ||
| US201962793645P | 2019-01-17 | 2019-01-17 | |
| US62/793,645 | 2019-01-17 | ||
| PCT/US2019/042447 WO2020018820A1 (en) | 2018-07-19 | 2019-07-18 | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117208A Division JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531005A JP2021531005A (ja) | 2021-11-18 |
| JP2021531005A5 true JP2021531005A5 (enExample) | 2022-07-25 |
| JP7319348B2 JP7319348B2 (ja) | 2023-08-01 |
Family
ID=67515169
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502831A Active JP7319348B2 (ja) | 2018-07-19 | 2019-07-18 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
| JP2023117208A Active JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117208A Active JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Country Status (34)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190320633A1 (en) | 2016-11-30 | 2019-10-24 | The Jackson Laboratory | Humanized mouse model with improved human innate immune cell development |
| KR102745676B1 (ko) | 2016-12-21 | 2024-12-24 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CA3063588A1 (en) | 2017-06-01 | 2018-12-06 | Regeneron Pharmaceuticals, Inc. | Human antibodies to bet v 1 and methods of use thereof |
| MX2021000532A (es) | 2018-07-19 | 2021-04-12 | Regeneron Pharma | Receptores antigénicos quiméricos con especificidad para bcma y usos de estos. |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| SG11202109002XA (en) * | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| SI3819007T1 (sl) | 2019-11-11 | 2024-10-30 | Amgen Inc. | Režim odmerjanja sredstev proti BCMA |
| CN114929343B (zh) * | 2019-12-06 | 2025-03-18 | 瑞泽恩制药公司 | 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法 |
| TW202144425A (zh) * | 2020-04-17 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 特異性抗原結合分子，其製備方法及醫藥用途 |
| WO2022002033A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 具有H2L2与HCAb结构的结合蛋白 |
| CA3177918A1 (en) | 2020-07-01 | 2022-01-06 | Amanda ATANASIO | Methods of treating allergy using anti-bet v 1 antibodies |
| CN116194105A (zh) * | 2020-09-14 | 2023-05-30 | 辉瑞大药厂 | 治疗癌症的方法、疗法及用途 |
| WO2022060901A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| EP4214234A1 (en) | 2020-09-18 | 2023-07-26 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
| CN118878694A (zh) * | 2020-11-23 | 2024-11-01 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| CN114573703A (zh) * | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种t细胞衔接器治疗剂的开发和应用 |
| PH12023500013A1 (en) | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| TW202246333A (zh) * | 2021-01-20 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途 |
| RS66868B1 (sr) | 2021-01-28 | 2025-06-30 | Regeneron Pharma | Kompozicije i postupci za lečenje sindroma oslobađanja citokina |
| CN115724996B (zh) * | 2021-08-30 | 2026-03-20 | 上海君赛生物股份有限公司 | 含有膜表面结构域的多肽及其用途 |
| CN118696058A (zh) | 2021-12-03 | 2024-09-24 | 山东先声生物制药有限公司 | 抗bcma纳米抗体及其应用 |
| CN118647724A (zh) * | 2021-12-22 | 2024-09-13 | 杰克逊实验室 | 人源化小鼠模型 |
| CA3247475A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS |
| CN117003871A (zh) | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 结合bcma和cd3的抗体及其用途 |
| CN119546644A (zh) | 2022-05-18 | 2025-02-28 | 瑞泽恩制药公司 | 结合cd38和4-1bb的多特异性抗原结合分子及其用途 |
| KR20250021313A (ko) | 2022-06-06 | 2025-02-12 | 산둥심시어 바이오파마슈티칼 씨오., 엘티디. | Bcma, gprc5d 및 t 세포를 표적으로 하는 다중특이적 항체 및 그 응용 |
| AR129560A1 (es) | 2022-06-08 | 2024-09-04 | Tidal Therapeutics Inc | Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos |
| CN115368466A (zh) * | 2022-07-19 | 2022-11-22 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| CN120282798A (zh) | 2022-10-10 | 2025-07-08 | 瑞泽恩制药公司 | 用于降低需要实体器官移植的受试者中的同种抗体水平的方法 |
| CN117186230B (zh) * | 2022-12-06 | 2024-04-16 | 成都赛恩吉诺生物科技有限公司 | 包含亲水性氨基酸的抗人bcma纳米抗体的双特异性抗体及应用 |
| JP2026506095A (ja) | 2023-02-17 | 2026-02-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN121335930A (zh) | 2023-06-06 | 2026-01-13 | 信达生物制药(苏州)有限公司 | 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途 |
| TW202517293A (zh) | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| WO2025131075A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3和抗cd3多特异性抗体及用途 |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| TW202543581A (zh) | 2024-02-12 | 2025-11-16 | 美商艾伊拉醫療公司 | 遞送組成物 |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| TW202543585A (zh) | 2024-03-08 | 2025-11-16 | 美商健臻公司 | 脂質奈米粒子 |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025240287A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies |
| WO2025244973A1 (en) | 2024-05-20 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026015729A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | Gprc5d x cd28 bispecific antibodies and methods of use thereof |
| WO2026059919A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors |
| WO2026059923A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator |
| WO2026059920A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors |
| WO2026059917A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors |
| WO2026059921A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors |
| WO2026072557A2 (en) | 2024-09-24 | 2026-04-02 | Genzyme Corporation | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
| WO2026072709A1 (en) | 2024-09-25 | 2026-04-02 | Orna Therapeutics, Inc. | Chimeric antigen receptors targeting bcma |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL211786B1 (pl) | 1999-08-17 | 2012-06-29 | Apoxis Sa | Zastosowanie przeciwciała oraz polipeptydu |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| DE10206325A1 (de) | 2002-02-14 | 2003-09-04 | Medinnova Ges Med Innovationen | Ummantelter Mikroorganismus |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| KR101589785B1 (ko) | 2009-03-10 | 2016-01-28 | 바이오젠 엠에이 인코포레이티드 | 항-ｂｃｍａ 항체 |
| LT2975051T (lt) | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| HRP20151188T4 (hr) | 2010-02-08 | 2021-10-01 | Regeneron Pharmaceuticals, Inc. | Miš sa zajedničkim lakim lancem |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| US20130273055A1 (en) | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| TWI638833B (zh) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| SI3415531T1 (sl) | 2011-05-27 | 2023-12-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - vezni proteini |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| ES3065694T3 (en) | 2012-04-11 | 2026-05-07 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| ES2937015T3 (es) | 2012-11-01 | 2023-03-23 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Anticuerpo contra CD269 (BCMA) |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US9963513B2 (en) | 2013-02-05 | 2018-05-08 | Engmab Sàrl | Method for the selection of antibodies against BCMA |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| US20180112384A1 (en) | 2013-12-30 | 2018-04-26 | Craig Rothleitner | Drainage treatment system |
| KR102526945B1 (ko) | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| BR112017010513A2 (pt) | 2014-11-20 | 2018-04-03 | F. Hoffmann-La Roche Ag | ?cadeias leves comuns e métodos de uso? |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| EP3872094A3 (en) | 2014-12-05 | 2021-12-08 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| SG11201704549UA (en) | 2014-12-05 | 2017-07-28 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| EP3971210A1 (en) | 2014-12-12 | 2022-03-23 | 2seventy bio, Inc. | Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors |
| TWI700298B (zh) | 2015-04-13 | 2020-08-01 | 美商輝瑞股份有限公司 | 靶向ｂ細胞成熟抗原之嵌合型抗原受體類 |
| IL310723A (en) | 2015-04-13 | 2024-04-01 | Pfizer | Therapeutic antibodies and their uses |
| CA2985816A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| WO2017031104A1 (en) * | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| KR102777500B1 (ko) * | 2015-09-23 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | 최적화된 항-cd3 이중특이적 항체 및 이의 용도 |
| AU2016353067B2 (en) | 2015-11-13 | 2023-10-05 | Sanford Research | Anti-BCMA polypeptides and proteins |
| US20190256608A1 (en) | 2015-12-01 | 2019-08-22 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| JOP20170017B1 (ar) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| SG11201805770UA (en) | 2016-02-03 | 2018-08-30 | Amgen Res Munich Gmbh | BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs |
| IL311107A (en) | 2016-02-17 | 2024-04-01 | Seagen Inc | BCMA antibodies and their use for the treatment of cancer and immune disorders |
| US10689450B2 (en) | 2016-04-01 | 2020-06-23 | Kite Pharma, Inc | BCMA binding molecules and methods of use thereof |
| US12048718B2 (en) | 2016-06-07 | 2024-07-30 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
| WO2018009904A2 (en) | 2016-07-08 | 2018-01-11 | Tumeh Paul C | Compositions and treatment methods for cancer immunotherapy |
| MY200988A (en) | 2016-09-14 | 2024-01-27 | Teneobio Inc | CD3 Binding Antibodies |
| US10738130B2 (en) * | 2016-09-23 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof |
| WO2018075359A1 (en) | 2016-10-18 | 2018-04-26 | Boger Henry William | Wireless power transfer for process control |
| EP3535295A1 (en) * | 2016-11-02 | 2019-09-11 | EngMab Sàrl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| WO2018099539A1 (en) | 2016-11-29 | 2018-06-07 | Horst Lindhofer | Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof |
| KR102745676B1 (ko) | 2016-12-21 | 2024-12-24 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| JP7280828B2 (ja) | 2017-01-23 | 2023-05-24 | クレージュ メディカル カンパニー，リミテッド | Ｂｃｍａを標的とする抗体およびその使用 |
| CA3049689A1 (en) | 2017-02-06 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| KR102700015B1 (ko) | 2017-05-05 | 2024-08-29 | 암젠 인크 | 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물 |
| IL312322B2 (en) | 2017-06-20 | 2026-05-01 | Teneobio Inc | Antibodies against BCMA containing only heavy chains |
| SG11202000499RA (en) | 2017-08-01 | 2020-02-27 | Medimmune Llc | Bcma monoclonal antibody-drug conjugate |
| US11447559B2 (en) | 2017-09-29 | 2022-09-20 | Mogam Institute For Biomedical Research | Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| CN107827989A (zh) | 2017-10-18 | 2018-03-23 | 银丰生物工程集团有限公司 | 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用 |
| CN110709425B (zh) | 2018-02-01 | 2022-09-16 | 南京驯鹿医疗技术有限公司 | 一种结合bcma的嵌合抗原受体（car）及其应用 |
| CN112912397B (zh) * | 2018-05-24 | 2025-03-14 | 詹森生物科技公司 | 抗cd3抗体及其用途 |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| SG11202109002XA (en) * | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
-
2019
- 2019-07-17 TW TW108125183A patent/TWI838389B/zh active
- 2019-07-18 SI SI201930882T patent/SI3823664T1/sl unknown
- 2019-07-18 ES ES19749096T patent/ES3010285T3/es active Active
- 2019-07-18 LT LTEPPCT/US2019/042447T patent/LT3823664T/lt unknown
- 2019-07-18 SM SM20250044T patent/SMT202500044T1/it unknown
- 2019-07-18 MD MDE20210483T patent/MD3823664T2/ro unknown
- 2019-07-18 KR KR1020217004615A patent/KR20210034032A/ko active Pending
- 2019-07-18 PL PL19749096.4T patent/PL3823664T3/pl unknown
- 2019-07-18 FI FIEP19749096.4T patent/FI3823664T3/fi active
- 2019-07-18 IL IL279974A patent/IL279974B2/en unknown
- 2019-07-18 MY MYPI2021000039A patent/MY201816A/en unknown
- 2019-07-18 PT PT197490964T patent/PT3823664T/pt unknown
- 2019-07-18 DK DK19749096.4T patent/DK3823664T3/da active
- 2019-07-18 CN CN201980047976.5A patent/CN112423785B/zh active Active
- 2019-07-18 RS RS20250180A patent/RS66535B1/sr unknown
- 2019-07-18 US US16/516,028 patent/US11384153B2/en active Active
- 2019-07-18 BR BR112021000186-7A patent/BR112021000186A2/pt unknown
- 2019-07-18 MA MA53168A patent/MA53168B1/fr unknown
- 2019-07-18 HR HRP20250199TT patent/HRP20250199T1/hr unknown
- 2019-07-18 SG SG11202100252SA patent/SG11202100252SA/en unknown
- 2019-07-18 WO PCT/US2019/042447 patent/WO2020018820A1/en not_active Ceased
- 2019-07-18 EP EP19749096.4A patent/EP3823664B1/en active Active
- 2019-07-18 MX MX2021000488A patent/MX2021000488A/es unknown
- 2019-07-18 JP JP2021502831A patent/JP7319348B2/ja active Active
- 2019-07-18 EP EP24212980.7A patent/EP4516810A3/en active Pending
- 2019-07-18 AU AU2019307928A patent/AU2019307928B2/en active Active
- 2019-07-18 HU HUE19749096A patent/HUE070224T2/hu unknown
-
2021
- 2021-01-06 ZA ZA2021/00087A patent/ZA202100087B/en unknown
- 2021-01-06 PH PH12021550031A patent/PH12021550031A1/en unknown
- 2021-01-13 CO CONC2021/0000188A patent/CO2021000188A2/es unknown
- 2021-01-13 MX MX2025005515A patent/MX2025005515A/es unknown
- 2021-01-15 CL CL2021000131A patent/CL2021000131A1/es unknown
-
2022
- 2022-05-31 US US17/828,847 patent/US12258412B2/en active Active
-
2023
- 2023-07-19 JP JP2023117208A patent/JP7586974B2/ja active Active
-
2025
- 2025-02-19 US US19/057,229 patent/US20260008862A1/en active Pending
- 2025-04-04 CY CY20251100235T patent/CY1127721T1/el unknown
- 2025-07-08 LT LTPA2025526C patent/LTPA2025526I1/lt unknown
- 2025-07-14 NL NL301335C patent/NL301335I2/nl unknown
- 2025-07-16 CY CY2025020C patent/CY2025020I1/el unknown
- 2025-07-29 FR FR25C1029C patent/FR25C1029I2/fr active Active
- 2025-08-05 HU HUS2500032C patent/HUS2500032I1/hu unknown
- 2025-08-07 NO NO2025036C patent/NO2025036I1/no unknown
- 2025-08-14 FI FIC20253006C patent/FIC20253006I1/fi unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3823664T3 (fi) | Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä | |
| CN107405397B (zh) | 抗tim-3抗体 | |
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| KR102340832B1 (ko) | 항 pd-1 항체 및 그의 용도 | |
| JP2023543152A5 (enExample) | ||
| JP2022515611A5 (enExample) | ||
| KR102838340B1 (ko) | 다중-특이적 항체 및 이들의 제조 및 사용 방법 | |
| JP2021527431A5 (enExample) | ||
| AU2023203119A1 (en) | Cd20 binding molecules and uses thereof | |
| JP2023505218A5 (enExample) | ||
| JP2021506244A5 (enExample) | ||
| EP3645741A2 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP2020528750A5 (enExample) | ||
| HRP20160009T1 (hr) | Protutijela anti-cd37 | |
| KR20170102167A (ko) | 항-pd-l1 항체 | |
| EP3341020A1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| JP2022533538A5 (enExample) | ||
| JP2020537520A (ja) | Ｃｄ１３７を標的とする抗体とその利用方法 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2022514734A5 (enExample) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| JP2024540148A5 (enExample) | ||
| JP2025511288A (ja) | 抗ｐｖｒｉｇ抗体、その医薬組成物及びその使用 | |
| CA3147887A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |